Hematological Malignancies Program

血液恶性肿瘤项目

• 批准号: 10378577
• 负责人: Charles G. Mullighan
• 金额: $ 7.02万
• 依托单位: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-04-01 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10378577
• 关键词: Academy; Acute Lymphocytic Leukemia; Acute Myelocytic Leukemia; Acute T Cell Leukemia; Acute leukemia; Adult; American; American Association for the Advancement of Science; Award; Basic Science; Biological; Biology; Biometry; Blood; Bone Marrow Transplantation; Cancer Biology; Cancer Center; Cancer Center Support Grant; Cancer Etiology; Cell Therapy; Childhood; Childhood Cancer Genome Project; Childhood Leukemia; Classification; Clinical; Clinical Research; Clinical Trials; Collaborations; Communicable Diseases; DNA Sequence Alteration; Development; Development Plans; Diagnosis; Disease; Disease Outcome; Drug Kinetics; Dysmyelopoietic Syndromes; Educational Activities; Engineering; Enrollment; Epigenetic Process; Faculty; Flow Cytometry; Foundations; Funding; Future; Genomics; Goals; Grant; Guidelines; Hematologic Neoplasms; Hematology; Heritability; Immunotherapeutic agent; Infant Leukemia; Inherited; International; Intervention; Laboratories; Lead; Leadership; Lymphoma; Medicine; Mentors; Molecular; NCI-Designated Cancer Center; Oncogenic; Oncology; Participant; Pathogenesis; Pathology; Pediatric Hematology; Pediatric Oncology Group; Peer Review; Pharmacogenetics; Pharmacologic Substance; Physicians; Pilot Projects; Precision medicine trial; Predisposition; Publications; Quality of life; Recurrent disease; Research; Research Personnel; Resource Sharing; Role; Saint Jude Children' s Research Hospital; Science; Seminal; Series; Societies; Strategic Planning; Survival Rate; Survivors; T-Lymphocyte; Testing; Therapeutic; Toxic effect; Translating; Translational Research; Translations; Treatment Efficacy; Treatment Side Effects; Treatment outcome; Treatment-related toxicity; United States National Institutes of Health; Work; World Health Organization; acute megakaryoblastic leukemia cell; childhood cancer mortality; clinical care; clinical investigation; clinical translation; disorder risk; driver mutation; high risk; improved; improved outcome; in vivo imaging; inter-institutional; leukemia; leukemia relapse; leukemia/lymphoma; meetings; member; mouse model; novel; novel diagnostics; novel therapeutics; patient derived xenograft model; pediatric department; precision medicine; preclinical study; programs; recruit; risk variant; standard of care; success; targeted treatment; translational pipeline; transplantation therapy; treatment response; working group

PROJECT SUMMARY/ABSTRACT–Hematological Malignancies Program The overall goal of the Hematological Malignancies Program (HMP) is to advance cure rates for pediatric leukemias and lymphomas while reducing toxicity of therapy. The HMP is an established, highly interactive, transdisciplinary program with a long track record of major discoveries in cancer biology, and the translation of these into new diagnostic and treatment approaches that have changed the standard of care of pediatric hematological malignancies. Charles Mullighan, MBBS (Hons), MD (laboratory lead) and Ching-Hon Pui, MD (clinical lead) are jointly responsible for the academic themes and direction of the Program. They bring together expertise spanning the basic-to-clinical spectrum that significantly enhances HMP activities and facilitates national and international collaborations. They align research efforts of the HMP with strategic goals of the SJCCC and identify inter-programmatic collaborative opportunities. HMP members participate in multiple intra- programmatic meetings and seminar series that facilitate transdisciplinary research, clinical, and educational activities. Program activities are organized into 3 working groups: Basic, Translational, and Clinical Research Groups. The HMP has 19 Full Members and 6 Associate (junior mentored) Members, including 3 members each of the National Academy of Medicine and the Association of American Physicians, 3 Fellows of the American Association for the Advancement of Science, and 5 members of the American Society for Clinical Investigation. Members are drawn from the Departments of Pediatric Medicine, Hematology, Infectious Diseases, Oncology, Pathology, Bone Marrow Transplantation & Cellular Therapy, and Pharmaceutical Sciences. HMP members have a total of $4.4M in annual peer-reviewed funding, including $2M in NCI funding and $1.6M in other NIH funding. Research from the HMP has resulted in 578 publications, of which 33.1% are intra-programmatic, 35.5% are inter-programmatic, and 77.5% are inter-institutional (many with other NCI-designated Cancer Centers). In addition, a total of 5 multi-investigator grants were awarded to the Program, two of which are inter-programmatic with CBP (P50GM115279) and CCSP and NBTP (U01CA195547). During the funding period (2013-2017) the HMP contributed 1134 interventional enrollments of which 1045 were therapeutic enrollments. By comparison, in the prior period (2008-2012) HMP had 973 interventional enrollments of which 885 were therapeutic. In addition, HMP contributed to the Center's overall transprogrammatic non-interventional studies totaling 30,071 accruals during the funding period. This includes 438 unique participants in specific HMP investigator driven non-interventional studies. During the current funding period, the HMP focused on common and clinically problematic hematological malignancies, including ALL, acute myeloid leukemia (AML), and relapsed leukemia. The Program also enriched research efforts in important but less well-characterized diseases, including infant leukemia, pediatric myelodysplasia, and lymphoma. HMP accomplishments have had national and global impact in the diagnosis, classification, and treatment of hematological malignancies.

项目摘要/摘要 - 途径Malignancys计划 血液学Malignancys计划（HMP）的总体目标是提高儿科治疗率 白血病和淋巴瘤，同时降低治疗的毒性。 HMP是一个建立的，高度互动的， 跨学科计划具有癌症生物学主要发现的悠久记录，并翻译 这些变成了改变小儿护理标准的新诊断和治疗方法 血液学恶性肿瘤。 MBBS（荣誉）的Charles Mullighan（实验室铅）和Ching-Hon Pui，医学博士 （临床负责人）对该计划的学术主题和方向共同负责。他们汇聚在一起 跨越基本到临床范围的专业知识可显着增强HMP活动并促进 国家和国际合作。他们使HMP的研究工作与 SJCCC并确定程序间的协作机会。 HMP成员参与多个内部 促进跨学科研究，临床和教育的程序化会议和节目系列 活动。计划活动分为3个工作组：基础，翻译和临床研究 组。 HMP有19个正式成员和6名合伙人（初中）成员，包括3个成员 美国国家医学院和美国医师协会的3个美国人 科学发展协会和美国临床研究学会的5名成员。 成员来自儿科医学，血液学，传染病，肿瘤学部门 病理学，骨髓移植和细胞疗法以及药物科学。 HMP成员 每年有440万美元的同行评审资金，包括200万美元的NCI资金和160万美元的其他NIH 资金。来自HMP的研究导致了578个出版物，其中33.1％是概括性的，35.5％ 是截面间的，77.5％是机构间的（许多与其他NCI指定的癌症中心）。 此外，该计划总共授予了5个多侵略器赠款 与CBP（P50GM115279）和CCSP和NBTP（U01CA195547）。在资金期（2013-2017）中 HMP贡献了1134次介入入学率，其中1045次是治疗性入学人数。相比之下， 在上一期（2008-2012）中，HMP有973次介入入学率，其中885个是治疗性的。 此外，HMP促进了该中心的整体外程编程非际交往研究，总计30,071 在资金期间的应计。这包括特定HMP调查员驱动器中的438位独特参与者 非间接研究。在当前的资金期间，HMP专注于普通和临床 有问题的血液系统恶性肿瘤，包括全部，急性髓样白血病（AML）和复发性白血病。 该计划还丰富了重要但特征较低的疾病的研究工作，包括婴儿 白血病，小儿骨髓增生和淋巴瘤。 HMP成就具有国家和全球影响 在诊断，分类和治疗血液系统恶性肿瘤中。